Risk of Venous Thromboembolism Linked with Comorbidity, Prostate Cancer
the Cancer Therapy Advisor take:
Increased venous thromboembolism (VTE) rates were clinically associated with prostate cancer (PC) and high comorbidity levels in patients, according to an article published online in the journal Cancer.
Participants in the study included 44,035 Danish patients with PC (diagnosed between 1995 and 2011) and 213,810 men from the general population. The participants were matched 5:1 on age, calendar time, and comorbidities.
Results showed 849 of the patients with PC and 2,360 of the men developed VTE within 5 years of follow-up. The patients with PC had a 2.2% risk of developing VTE, while the general population male group had a 1.3% risk.
Patients with PC and high comorbidity levels had a 1-year standardized VTE rate of 15 per 1,000 person-years (PYs) (95% CI: 6.8, 24 per 1,000 PYs)—29% of this rate was attributed to an interaction between PC and comorbidity.
Older patients, patients with metastases, those with a high Gleason score, those in the D’Amico high-risk group, and patients who had surgery were also at a greater risk for developing VTE.
The study suggests that controlling and reducing VTEs associated with comorbidities may influence the overall risk of developing VTE and potentially affect prognosis.
Editor's note: The original version of this article stated that there was a clinical association between pancreatic cancer and VTE, the article has been corrected to reflect the association between VTE and prostate cancer.
Increased venous thromboembolism rates were clinically associated with prostate cancer and high comorbidity levels.
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Long-term Survival From Ipilimumab/Nivolumab Combination in Metastatic Melanoma
- Lung Cancer Treatment in North America: Recent Advances and Future Promises
- Pembrolizumab Significantly Prolongs OS Compared With Chemotherapy in NSCLC
- Nivolumab Plus Chemotherapy Improves Overall Survival and Response Rate in NSCLC
- FDA Approves Axicabtagene Ciloleucel for Non-Hodgkin Lymphoma, Questions Remain About Cost and Toxicity
- FDA Grants Breakthrough Therapy Designation to Adjuvant Dabrafenib Plus Trametinib for Melanoma
- Long-term Eltrombopag Improves Outcomes in Chronic Immune Thrombocytopenia
- Phase 1 Trial of Guadecitabine With Vaccine and Cyclophosphamide for Metastatic Colorectal Cancer
- Success of Adoptive Cell Therapy in ALL Could Be Applied to Myeloma
- Curative-intent Surgery for Cancer Increases Risk of New Persistent Opioid-use